Login to Your Account



In The Clinic NEWS

Reata Pharmaceuticals Inc.'s chief medical officer, Colin Meyer, told BioWorld Today that an earlier phase III trial in CKD was stopped because of "a very specific safety finding that we did not understand at the time."

Jeff Abbey, president and CEO of Argos Therapeutics Inc., needed all of three minutes to deliver the news that Argos was stopping the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T.

Trevena Inc. reported top-line results from its pivotal phase III APOLLO-1 and -2 efficacy studies of lead candidate oliceridine in moderate to severe acute pain following bunionectomy and abdominoplasty, respectively.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: